Meijun Xiong

Title: Meijun Xiong: Innovator in Antibody-Drug Conjugate Technology

Introduction

Meijun Xiong is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 2 patents, his work is paving the way for advancements in targeted cancer therapies.

Latest Patents

Meijun Xiong's latest patents include innovative methods for preparing antibody-drug conjugates. One of his notable inventions is the "Immobilized endoglycosidase fusion protein and use thereof." This method involves the formation of an antibody-drug conjugate through site-directed conjugation based on an N-glycosylation site of an Fc region of an antibody. The process includes providing a donor with an oxazoline oligosaccharide, an antibody with a GlcNAc motif, and an immobilized endoglycosidase. The catalytic action of the endoglycosidase allows for a one-step conjugation process. Additionally, he has developed a linker-payload compound that includes an oligosaccharide group, which is linked to an antibody-drug conjugate, enhancing the efficacy of the treatment.

Career Highlights

Meijun Xiong is currently employed at Genequantum Healthcare (Suzhou) Co., Ltd. His work at this company focuses on the development of innovative biopharmaceuticals. His expertise in glycosylation and antibody engineering has positioned him as a key player in the biotechnology sector.

Collaborations

Meijun collaborates with talented individuals such as Gang Qin and Mingyu Hu. Their combined efforts contribute to the advancement of research and development in the field of antibody-drug conjugates.

Conclusion

Meijun Xiong's contributions to biotechnology, particularly in antibody-drug conjugate technology, highlight his role as an influential inventor. His innovative patents and collaborations are set to make a significant impact on cancer treatment methodologies.